drugset / Trial / NCT06447701
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
Phase 3
Not yet recruiting
486 enrolled
Zhujiang Hospital
Central People's Hospital of Zhanjiang · collabEighth Affiliated Hospital, Sun Yat-sen University · collabGuangdong Provincial People's Hospital · collabGuangzhou First People's Hospital · collabPeking University Shenzhen Hospital · collabShantou Central Hospital · collabShenzhen Second People's Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.
Timeline
- Start
- 2025-10-30
- Primary completion
- 2025-12-31
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 320 mg | Intravenous |